Raras
Buscar doenças, sintomas, genes...
Distonia-Parkinsonismo ligado ao X
ORPHA:53351CID-10 · G24.1CID-11 · 8A00.20OMIM 314250PCDT · SUSDOENÇA RARA

A distonia-parkinsonismo ligada ao cromossomo X (XDP) é uma doença neurológica progressiva que afeta os movimentos. Ela é caracterizada pelo surgimento, na idade adulta, de sintomas parecidos com os da Doença de Parkinson, frequentemente acompanhados por distonia focal, que são contrações musculares involuntárias em uma parte específica do corpo. Com o tempo, essas contrações podem se espalhar para outras partes do corpo. A forma como a doença se manifesta e evolui varia muito de uma pessoa para outra.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A distonia-parkinsonismo ligada ao cromossomo X (XDP) é uma doença neurológica progressiva que afeta os movimentos. Ela é caracterizada pelo surgimento, na idade adulta, de sintomas parecidos com os da Doença de Parkinson, frequentemente acompanhados por distonia focal, que são contrações musculares involuntárias em uma parte específica do corpo. Com o tempo, essas contrações podem se espalhar para outras partes do corpo. A forma como a doença se manifesta e evolui varia muito de uma pessoa para outra.

Publicações científicas
183 artigos
Último publicado: 2026

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
<1 / 1 000 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Europe
Início
Adult
🏥
SUS: Cobertura parcialScore: 45%
PCDT disponívelCID-10: G24.1
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (2)
0202010694
Sequenciamento completo do exoma (WES)genetic_test
0301070040
Atendimento em reabilitação — doenças rarasrehabilitation
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

💪
Músculos
5 sintomas
🧠
Neurológico
3 sintomas
🫁
Pulmão
1 sintomas

+ 13 sintomas em outras categorias

Características mais comuns

55%prev.
Distonia focal
Frequente (79-30%)
55%prev.
Mioclonias
Frequente (79-30%)
55%prev.
Distonia de torção
Frequente (79-30%)
55%prev.
Blefaroespasmo
Frequente (79-30%)
55%prev.
Tremor de repouso
Frequente (79-30%)
55%prev.
Tremor na mão
Frequente (79-30%)
22sintomas
Frequente (12)
Ocasional (7)
Sem dados (3)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 22 características clínicas mais associadas, ordenadas por frequência.

Distonia focalFocal dystonia
Frequente (79-30%)55%
MiocloniasMyoclonus
Frequente (79-30%)55%
Distonia de torçãoTorsion dystonia
Frequente (79-30%)55%
BlefaroespasmoBlepharospasm
Frequente (79-30%)55%
Tremor de repousoResting tremor
Frequente (79-30%)55%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico183PubMed
Últimos 10 anos145publicações
Pico202124 papers
Linha do tempo
2026Hoje · 2026🧪 2017Primeiro ensaio clínico📈 2021Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

1 gene identificado com associação a esta condição. Padrão de herança: Not applicable, X-linked recessive.

TAF1Transcription initiation factor TFIID subunit 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

The TFIID basal transcription factor complex plays a major role in the initiation of RNA polymerase II (Pol II)-dependent transcription (PubMed:33795473). TFIID recognizes and binds promoters with or without a TATA box via its subunit TBP, a TATA-box-binding protein, and promotes assembly of the pre-initiation complex (PIC) (PubMed:33795473). The TFIID complex consists of TBP and TBP-associated factors (TAFs), including TAF1, TAF2, TAF3, TAF4, TAF5, TAF6, TAF7, TAF8, TAF9, TAF10, TAF11, TAF12 an

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (9)
Regulation of TP53 Activity through PhosphorylationRNA Polymerase II Promoter EscapeRNA Polymerase II HIV Promoter EscapeRNA Polymerase II Pre-transcription EventsHIV Transcription Initiation
MECANISMO DE DOENÇA

Dystonia 3, torsion, X-linked

An X-linked dystonia-parkinsonism disorder. Dystonia is defined by the presence of sustained involuntary muscle contractions, often leading to abnormal postures. DYT3 is characterized by severe progressive torsion dystonia followed by parkinsonism. It has a well-defined pathology of extensive neuronal loss and mosaic gliosis in the striatum (caudate nucleus and putamen) which appears to resemble that in Huntington disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Útero
26.5 TPM
Cervix Endocervix
26.3 TPM
Ovário
25.0 TPM
Cervix Ectocervix
23.9 TPM
Fallopian Tube
23.4 TPM
OUTRAS DOENÇAS (2)
intellectual disability, X-linked, syndromic 33X-linked dystonia-parkinsonism
HGNC:11535UniProt:P21675

Variantes genéticas (ClinVar)

336 variantes patogênicas registradas no ClinVar.

🧬 TAF1: NM_004606.5(TAF1):c.3127G>A (p.Gly1043Arg) ()
🧬 TAF1: NM_004606.5(TAF1):c.3963G>T (p.Gly1321=) ()
🧬 TAF1: NM_004606.5(TAF1):c.3599C>G (p.Thr1200Ser) ()
🧬 TAF1: NM_004606.5(TAF1):c.2034T>A (p.Asp678Glu) ()
🧬 TAF1: NM_004606.5(TAF1):c.2809A>G (p.Arg937Gly) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 19 variantes classificadas pelo ClinVar.

2
11
6
Patogênica (10.5%)
VUS (57.9%)
Benigna (31.6%)
VARIANTES MAIS SIGNIFICATIVAS
TAF1: NM_004606.5(TAF1):c.235+3G>A [Conflicting classifications of pathogenicity]
TAF1: NG_012771.2:g.79230_79231ins[AB191243.1:g.261508_264134] [Pathogenic]
TAF1: NM_004606.5(TAF1):c.4265T>G (p.Ile1422Ser) [Uncertain significance]
TAF1: NM_004606.5(TAF1):c.905C>T (p.Pro302Leu) [Uncertain significance]
TAF1: NM_004606.5(TAF1):c.694C>A (p.Pro232Thr) [Uncertain significance]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
·Pré-clínico3
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 3 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Distonia-Parkinsonismo ligado ao X

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

3 ensaios clínicos encontrados.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
127 papers (10 anos)
#1

Alterations in energy production in a Drosophila model for the X-linked dystonia-parkinsonism-related Taf1 deficiency.

Frontiers in aging neuroscience2026

X-linked dystonia-parkinsonism (XDP), an adult-onset neurodegenerative disorder, is caused by an SVA insertion in the TAF1 gene, containing a hexanucleotide, the length of which is correlated to the severity of the disease. The SVA insertion moderately disrupts gene expression; however, the underlying disease mechanism remains enigmatic. Here, we characterized a fly model for Taf1 deficiency and performed a pilot RNA sequencing analysis. Subsequently, we validated these findings in Taf1-deficient flies and in XDP patient-derived fibroblasts. We identified an upregulation of genes involved in lipid-dependent energy production as a compensatory mechanism to maintain proper ATP levels. However, studies in XDP patient-derived fibroblasts with minor TAF1 reduction did not confirm these findings. β-oxidation is elevated in flies with severe TAF1 reduction but not detected in XDP-patient fibroblasts, suggesting that this compensatory mechanism may only manifest above a critical TAF1 dosage threshold, absent in patient basal conditions. This finding thus suggests that dosage-dependent metabolic responses occur following TAF1 loss.

#2

MSH3 is a genetic modifier of somatic repeat instability in X-linked dystonia parkinsonism.

American journal of human genetics2026 Jan 08

X-linked dystonia parkinsonism (XDP) is a progressive adult-onset neurogenerative disorder caused by the insertion of a SINE-VNTR-Alu (SVA) retrotransposon in TAF1. One element of the SVA is a tandem polymorphic CCCTCT repeat tract whose length inversely correlates with the age of disease onset. Previous observations that the repeat exhibits length-dependent somatic expansion and that XDP onset is modified by variation in DNA repair gene MSH3 indicated that somatic repeat expansion is an important disease driver. Here, we sought to uncover genetic modifiers of CCCTCT instability in XDP individuals and to provide a mechanistic link between somatic instability and disease. We determined quantitative metrics of both repeat expansion and repeat contraction in blood. Using genetic association analyses of exome sequencing data and directed sequencing of a variant MSH3 repeat, we found that MSH3 modifies repeat expansion and contraction in blood as well as age at onset. MSH3 alleles associated with earlier disease onset were associated with more expansion and less contraction. Conversely, alleles associated with later disease onset were associated with less expansion and more contraction. Notably, MSH3 repeat alleles were also similarly associated with expansion and contraction in brain tissues. Our findings provide key evidence that the role of MSH3 in CCCTCT repeat dynamics underlies its impact on clinical disease and indicate that therapeutic strategies to lower or inhibit MSH3 are predicted to both slow CCCTCT expansion and promote CCCTCT contraction, impacting the disease course prior to clinical onset.

#3

Therapeutic targeting of alternative splicing caused by a lethal noncoding structural variant in X-linked dystonia parkinsonism.

medRxiv : the preprint server for health sciences2025 Oct 13

X-linked Dystonia-Parkinsonism (XDP) is a lethal adult-onset neurodegenerative disorder that exhibits features of dystonia and parkinsonism and is exclusively associated with a causal founder haplotype that is indigenous to the Philippines and affects Filipino males. Using patient-specific fibroblasts, neural stem cells (NSC), and other neuronal models, we discovered that cryptic alternative splicing caused by a novel SINE-VNTR-Alu (SVA) mobile element insertion into intron 32 of TAF1 is a mechanistic hallmark of XDP. We leveraged postmortem brain samples from an XDP-specific brain bank to demonstrate that the molecular hallmarks of XDP observed in neural stem cells (NSCs) mirror abnormalities observed in brain tissues from affected patients. Based on these findings that patient-specific NSCs reproduce mechanistic signatures found in the brain, we sought to develop a bespoke precision therapeutic for XDP and evaluate its relative efficacy in ameliorating transcriptomic signatures in neuronal models. We first used CRISPR-based excision of the SVA and demonstrated ablation of all aberrant splicing and dysregulation of TAF1 expression in NSCs across 30 independent clones. CRISPR-based correction of the XDP haplotype also restored the expression of 424 of 1,490 (30%) differentially expressed genes (DEGs) that were altered in XDP patient lines and greatly exceeded what would be expected by chance (p-value = 9.89e-87). While in vivo delivery of a gold standard CRISPR therapy is currently not feasible for XDP, we evaluated a tractable approach for Filipino patients by exploring the potential to modulate alternative splicing in XDP patients using antisense oligonucleotides (ASOs). To accomplish this, we developed a large-scale and well controlled functional genomics platform that screened eighty ASOs targeting intron 32 of XDP patients, followed by prioritization of lead ASOs based on attenuation of the alternative splicing signature. In transcriptome analyses across 1,550 libraries, we found that 8 of the 12 lead ASOs ameliorated the targeted XDP aberrant splicing. Moreover, we found that the two lead ASOs exhibited 38% and 43% rescue of XDP-specific DEGs that were also rescued by CRISPR excision of the SVA (enrichment p-values = 2.06e-13 and 2.27e-05, respectively). These rescues represented restoration of key molecular functions previously implicated in XDP, such as synaptic function, DNA-binding transcription factor activity, and gliogenesis. This study highlights a path to a potential targeted therapeutic for XDP and the capacity to exploit functional genomic signatures in patient-derived neural models to develop a scalable precision therapeutic platform for rare genetic disorders.

#4

A hexamer tandem repeat RNA embedded within an SVA retrotransposon drives R-loop formation and neurodegeneration.

Cell reports2025 Jul 22

Retrotransposon activation is emerging as a significant factor in neurodegenerative disease pathogenesis. SINE-VNTR-Alu (SVAs) are hominid-specific retrotransposons that create genetic variation through insertion polymorphisms and variable short tandem repeat (STR) lengths. We investigate how the SVA (CCCTCT)n STR contributes to the striatal neurodegenerative disorder X-linked dystonia parkinsonism (XDP), where the repeat expansion length within the pathogenic SVA is inversely correlated with age at disease onset. Phenotypic and transcriptomic analysis of XDP and isogenic SVA-deleted striatal organoids reveal that the SVA insertion drives hallmarks of neurodegeneration, including transcriptional dysregulation, decreased neuronal activity, and apoptosis, which are ameliorated by SVA deletion. We identify an (AGAGGG)n hexamer-containing RNA in the XDP-causing SVA that increases expression during organoid maturation and drives R-loop formation in organoids and brain tissue. Knockdown of the hexamer-containing RNA by antisense oligonucleotides rescues apoptosis in XDP organoids. We demonstrate that a retrotransposon-derived tandem repeat RNA may cause neurodegeneration.

#5

Engineering of CD63 Enables Selective Extracellular Vesicle Cargo Loading and Enhanced Payload Delivery.

Journal of extracellular vesicles2025 Jun

Extracellular vesicles (EVs) are mediators of intercellular communication through the transfer of nucleic acids, lipids and proteins between cells. This property makes bioengineered EVs promising therapeutic vectors. However, it remains challenging to isolate EVs with a therapeutic payload due to the heterogeneous nature of cargo loading into EVs. In this study, enrichment of EVs with a desired cargo was possible through engineering of the hallmark CD63 transmembrane protein. E-NoMi refers to engineered CD63 with mCherry on the inside of the EV membrane and a tag (3xFLAG) exposed on the outside of the EV membrane. To facilitate EV loading during biogenesis, cargo proteins, such as EGFP, Cre recombinase and the CRISPR-Cas nuclease (SaCas9), were fused to a nanobody (Nb) protein with a high affinity for mCherry. FLAG-tag-based immunocapture from cell conditioned media allowed selection of cargo-loaded E-NoMi-EVs, and tobacco etch virus (TEV) protease cleavage sites were used to remove the 3xFLAG-tag from the surface of E-NoMi-EVs after capture. For functional payload delivery to recipient cells, the vesicular stomatitis virus G (VSV-G) fusogenic protein was incorporated into E-NoMi-EVs to form fusogenic EV-based vectors (EVVs) and proved to be 10-fold more effective at cargo delivery than EVs generated by size-exclusion chromatography. Functional delivery of cargo with E-NoMi-EVVs was validated in two mouse brain models in vivo.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC137 artigos no totalmostrando 141

2026

Alterations in energy production in a Drosophila model for the X-linked dystonia-parkinsonism-related Taf1 deficiency.

Frontiers in aging neuroscience
2026

MSH3 is a genetic modifier of somatic repeat instability in X-linked dystonia parkinsonism.

American journal of human genetics
2025

Therapeutic targeting of alternative splicing caused by a lethal noncoding structural variant in X-linked dystonia parkinsonism.

medRxiv : the preprint server for health sciences
2025

Genome writing to dissect consequences of SVA retrotransposon disease X-Linked Dystonia Parkinsonism.

bioRxiv : the preprint server for biology
2025

Myelin pathology is a key feature of X-linked Dystonia Parkinsonism.

bioRxiv : the preprint server for biology
2025

Anesthesia Management for High-Intensity Focused Ultrasound (HIFU) Thalamotomy for Movement Disorders: A Case Series from the National University Hospital of the Philippines.

Acta medica Philippina
2025

A hexamer tandem repeat RNA embedded within an SVA retrotransposon drives R-loop formation and neurodegeneration.

Cell reports
2025

Engineering of CD63 Enables Selective Extracellular Vesicle Cargo Loading and Enhanced Payload Delivery.

Journal of extracellular vesicles
2025

Globally Reduced Brain Volume in Rett Syndrome.

Pediatric neurology
2025

Cerulenin partially corrects the disrupted developmental transcriptomic signature in Huntington's disease striatal medium spiny neurons.

Stem cells (Dayton, Ohio)
2025

The tongue muscles: Clinical applications in lingual dystonia.

Toxicon : official journal of the International Society on Toxinology
2025

X-Linked Dystonia-Parkinsonism in a Manifesting Female: First Case Report of Deep Brain Stimulation.

Movement disorders clinical practice
2025

GLP-1 agonists to slow down Parkinson's progression? The quest continues.

Med (New York, N.Y.)
2025

Retrotransposon: an insight into neurological disorders from perspectives of neurodevelopment and aging.

Translational neurodegeneration
2025

Non-invasive detection of allele-specific CRISPR-SaCas9-KKH disruption of TOR1A DYT1 allele in a xenograft mouse model.

Molecular therapy. Nucleic acids
2025

Clinical Outcomes with Prospective Brain Sensing Data Following Bilateral Globus Pallidus Deep Brain Stimulation in X-Linked Dystonia Parkinsonism.

Movement disorders clinical practice
2025

Principal variables analysis for non-Gaussian data.

Journal of computational and graphical statistics : a joint publication of American Statistical Association, Institute of Mathematical Statistics, Interface Foundation of North America
2025

Genomic characterization of Huntington's disease genetic modifiers informs drug target tractability.

Brain communications
2025

Promoting Physical Activity in People With Parkinson's Disease Through a Smartphone App: A Pilot Study.

Journal of neurologic physical therapy : JNPT
2024

Triplex H-DNA structure: the long and winding road from the discovery to its role in human disease.

NAR molecular medicine
2024

Dysphagia is a risk factor of malnutrition in X-linked Dystonia-Parkinsonism.

Clinical parkinsonism &amp; related disorders
2025

Endometrioma patients are under-treated with endocrine endometriosis therapy.

Human reproduction (Oxford, England)
2024

Targeting Myeloperoxidase to Reduce Neuroinflammation in X-Linked Dystonia Parkinsonism.

CNS neuroscience &amp; therapeutics
2024

Clinicodemographic and Genetic Modifier Correlation in an X-Linked Dystonia-Parkinsonism Cohort from Mindanao.

Movement disorders clinical practice
2024

The roles of TAF1 in neuroscience and beyond.

Royal Society open science
2024

G-quadruplexes in an SVA retrotransposon cause aberrant TAF1 gene expression in X-linked dystonia parkinsonism.

Nucleic acids research
2024

ZNF91 is an endogenous repressor of the molecular phenotype associated with X-linked dystonia-parkinsonism (XDP).

Proceedings of the National Academy of Sciences of the United States of America
2024

Establishing and developing a magnetic resonance-guided focused ultrasound program in a resource-limited setting: the Philippine experience.

Neurosurgical review
2024

Motor assessment of X-linked dystonia parkinsonism via machine-learning-based analysis of wearable sensor data.

Scientific reports
2025

Islands and Neurology: An Exploration into a Unique Association.

The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry
2024

Mini-heterochromatin domains constrain the cis-regulatory impact of SVA transposons in human brain development and disease.

Nature structural &amp; molecular biology
2024

Taf1 knockout is lethal in embryonic male mice and heterozygous females show weight and movement disorders.

Disease models &amp; mechanisms
2024

SAK3 confers neuroprotection in the neurodegeneration model of X-linked Dystonia-Parkinsonism.

Research square
2024

Stability of Mosaic Divergent Repeat Interruptions in X-Linked Dystonia-Parkinsonism.

Movement disorders : official journal of the Movement Disorder Society
2024

Neuroenergetic Changes in Patients with X-Linked Dystonia-Parkinsonism and Female Carriers.

Movement disorders clinical practice
2024

Oral diadochokinetic markers of X-linked dystonia-parkinsonism.

Parkinsonism &amp; related disorders
2024

A scoping review on the diagnosis and treatment of X-linked dystonia-parkinsonism.

Parkinsonism &amp; related disorders
2024

Proteomic analysis of X-linked dystonia parkinsonism disease striatal neurons reveals altered RNA metabolism and splicing.

Neurobiology of disease
2023

Applicability of clinical genetic testing for deep brain stimulation treatment in monogenic Parkinson's disease and monogenic dystonia: a multidisciplinary team perspective.

Frontiers in neuroscience
2024

Longitudinal predictors of health-related quality of life in isolated dystonia.

Journal of neurology
2023

The STEPWISE study: study protocol for a smartphone-based exercise solution for people with Parkinson's Disease (randomized controlled trial).

BMC neurology
2023

iPSC motor neurons, but not other derived cell types, capture gene expression changes in postmortem sporadic ALS motor neurons.

Cell reports
2023

Transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomy for patients with X-linked dystonia-parkinsonism: a study protocol.

BMC neurology
2023

A Network Imaging Biomarker of X-Linked Dystonia-Parkinsonism.

Annals of neurology
2023

Nine Hereditary Movement Disorders First Described in Asia: Their History and Evolution.

Journal of movement disorders
2023

The vital role of natural history studies in rare disease: insights from X-linked dystonia parkinsonism.

Brain communications
2023

Establishing a natural history of X-linked dystonia parkinsonism.

Brain communications
2023

The Effect of Glucocorticoids on TAF1 Gene Transcription in X-linked Dystonia Parkinsonism.

Journal of the ASEAN Federation of Endocrine Societies
2023

Mechanisms underlying phenotypic variation in neurogenetic disorders.

Nature reviews. Neurology
2023

Tracking human neurologic disease status in mouse brain/plasma using reporter-tagged, EV-associated biomarkers.

Molecular therapy : the journal of the American Society of Gene Therapy
2023

Oculomotor abnormalities indicate early executive dysfunction in prodromal X-linked dystonia-parkinsonism (XDP).

Journal of neurology
2023

Basal Ganglia Atrophy as a Marker for Prodromal X-Linked Dystonia-Parkinsonism.

Annals of neurology
2023

X-linked dystonia parkinsonism: epidemiology, genetics, clinical features, diagnosis, and treatment.

Acta neurologica Belgica
2022

Postnatal Conditional Deletion of Bcl11b in Striatal Projection Neurons Mimics the Transcriptional Signature of Huntington's Disease.

Biomedicines
2022

Repeat-Associated Non-AUG Translation of AGAGGG Repeats that Cause X-Linked Dystonia-Parkinsonism.

Movement disorders : official journal of the Movement Disorder Society
2022

Factors influencing reduced penetrance and variable expressivity in X-linked dystonia-parkinsonism.

Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V
2022

Variation in TAF1 expression in female carrier induced pluripotent stem cells and human brain ontogeny has implications for adult neostriatum vulnerability in X-linked Dystonia Parkinsonism.

eNeuro
2022

Prodromal X-Linked Dystonia-Parkinsonism is Characterized by a Subclinical Motor Phenotype.

Movement disorders : official journal of the Movement Disorder Society
2023

Mosaic divergent repeat interruptions in XDP influence repeat stability and disease onset.

Brain : a journal of neurology
2022

Association Study of TAF1 Variants in Parkinson's Disease.

Frontiers in neuroscience
2022

Tissue-specific and repeat length-dependent somatic instability of the X-linked dystonia parkinsonism-associated CCCTCT repeat.

Acta neuropathologica communications
2022

Monogenic Parkinson's Disease: Genotype, Phenotype, Pathophysiology, and Genetic Testing.

Genes
2022

Biopsychosocial Aspect of Patients With X-Linked Dystonia-Parkinsonism: Its Implications on Quality of Life.

Cureus
2022

Transcriptional Alterations in X-Linked Dystonia-Parkinsonism Caused by the SVA Retrotransposon.

International journal of molecular sciences
2022

Elucidating Hexanucleotide Repeat Number and Methylation within the X-Linked Dystonia-Parkinsonism (XDP)-Related SVA Retrotransposon in TAF1 with Nanopore Sequencing.

Genes
2022

Using genetically modified extracellular vesicles as a non-invasive strategy to evaluate brain-specific cargo.

Biomaterials
2021

X-linked dystonia-parkinsonism: over and above a repeat disorder.

Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V
2021

A Cross-Cultural Validation of the Filipino and Hiligaynon Versions of the Parts IIIB (Non-Motor Features) and IV (Activities of Daily Living) of the X-Linked Dystonia-Parkinsonism- MDSP Rating Scale.

Clinical parkinsonism &amp; related disorders
2021

Spectrum of Movement Disorders in two Movement Disorders Centers in the Philippines.

Acta neurologica Taiwanica
2021

Ataxia with vitamin E deficiency in the Philippines : A case report of two siblings.

The journal of medical investigation : JMI
2021

Dissection of TAF1 neuronal splicing and implications for neurodegeneration in X-linked dystonia-parkinsonism.

Brain communications
2021

Dystonia-specific mutations in THAP1 alter transcription of genes associated with neurodevelopment and myelin.

American journal of human genetics
2022

X-Linked Dystonia-Parkinsonism ("Lubag") May Present with Peripheral Synucleinopathy.

Movement disorders : official journal of the Movement Disorder Society
2021

The HIV protease inhibitor, ritonavir, corrects diverse brain phenotypes across development in mouse model of DYT-TOR1A dystonia.

Science translational medicine
2021

Striatal Cholinergic Dysregulation after Neonatal Decrease in X-Linked Dystonia Parkinsonism-Related TAF1 Isoforms.

Movement disorders : official journal of the Movement Disorder Society
2021

Speech and swallowing deficits in X-Linked Dystonia-Parkinsonism.

Parkinsonism &amp; related disorders
2021

Brain Regional Differences in Hexanucleotide Repeat Length in X-Linked Dystonia-Parkinsonism Using Nanopore Sequencing.

Neurology. Genetics
2021

Identifying genetic modifiers of age-associated penetrance in X-linked dystonia-parkinsonism.

Nature communications
2021

Impact of deep brain stimulation on quality of life and motor symptoms in Parkinson's disease and X-linked dystonia parkinsonism: The Philippine experience.

Parkinsonism &amp; related disorders
2021

X-Linked Parkinsonism: Phenotypic and Genetic Heterogeneity.

Movement disorders : official journal of the Movement Disorder Society
2021

Transcranial Magnetic Resonance-Guided Focused Ultrasound in X-Linked Dystonia-Parkinsonism.

Life (Basel, Switzerland)
2021

X-linked dystonia Parkinsonism: crossing a new threshold.

Journal of neural transmission (Vienna, Austria : 1996)
2021

Neurocognitive profile of patients with X-linked dystonia-parkinsonism.

Journal of neural transmission (Vienna, Austria : 1996)
2020

Pallidal Deep Brain Stimulation for Monogenic Dystonia: The Effect of Gene on Outcome.

Frontiers in neurology
2021

Bilateral vestibulopathy in anti-IgLON5 disease.

Journal of neurology
2021

Therapies for Genetic Forms of Parkinson's Disease: Systematic Literature Review.

Journal of neuromuscular diseases
2021

Promise and challenges of dystonia brain banking: establishing a human tissue repository for studies of X-Linked Dystonia-Parkinsonism.

Journal of neural transmission (Vienna, Austria : 1996)
2023

Progressive Decline in Voice and Voice-Related Quality of Life in X-Linked Dystonia Parkinsonism.

Journal of voice : official journal of the Voice Foundation
2020

SVA insertion in X-linked Dystonia Parkinsonism alters histone H3 acetylation associated with TAF1 gene.

PloS one
2021

Isolated dystonia: clinical and genetic updates.

Journal of neural transmission (Vienna, Austria : 1996)
2021

Retroelement-derived RNA and its role in the brain.

Seminars in cell &amp; developmental biology
2021

Neuroimaging and neuropathology studies of X-linked dystonia parkinsonism.

Neurobiology of disease
2021

Combined dystonias: clinical and genetic updates.

Journal of neural transmission (Vienna, Austria : 1996)
2020

Corrigendum: Translation, Cultural Adaptation, and Validation of the Hiligaynon Montreal Cognitive Assessment Tool (MoCA-Hil) Among Patients With X-Linked Dystonia Parkinsonism (XDP).

Frontiers in neurology
2021

TAF1 Transcripts and Neurofilament Light Chain as Biomarkers for X-linked Dystonia-Parkinsonism.

Movement disorders : official journal of the Movement Disorder Society
2020

Linking Huntington's Disease and X-linked Dystonia Parkinsonism on the Molecular Level.

Movement disorders : official journal of the Movement Disorder Society
2020

Expanding Data Collection for the MDSGene Database: X-linked Dystonia-Parkinsonism as Use Case Example.

Movement disorders : official journal of the Movement Disorder Society
2020

DNA Methylation as a Potential Molecular Mechanism in X-linked Dystonia-Parkinsonism.

Movement disorders : official journal of the Movement Disorder Society
2020

Neuroinflammation and histone H3 citrullination are increased in X-linked Dystonia Parkinsonism post-mortem prefrontal cortex.

Neurobiology of disease
2020

Pathogenic SREK1 decrease in Huntington's disease lowers TAF1 mimicking X-linked dystonia parkinsonism.

Brain : a journal of neurology
2020

Phasic Knee Bending Dystonic and Parkinsonian Gait: A Characteristic Finding in X-Linked Dystonia Parkinsonism.

Movement disorders clinical practice
2019

Translation, Cultural Adaptation, and Validation of the Hiligaynon Montreal Cognitive Assessment Tool (MoCA-Hil) Among Patients With X-Linked Dystonia Parkinsonism (XDP).

Frontiers in neurology
2020

Risk of spread in adult-onset isolated focal dystonia: a prospective international cohort study.

Journal of neurology, neurosurgery, and psychiatry
2020

Quality of life outcomes after deep brain stimulation in dystonia: A systematic review.

Parkinsonism &amp; related disorders
2020

Neuronal-specific microexon splicing of TAF1 mRNA is directly regulated by SRRM4/nSR100.

RNA biology
2019

Imaging gradual neurodegeneration in a basal ganglia model disease.

Annals of neurology
2019

Cost-Analysis of the Different Treatment Modalities in X-Linked Dystonia-Parkinsonism.

Frontiers in neurology
2019

X-Linked Dystonia-Parkinsonism: recent advances.

Current opinion in neurology
2019

A hexanucleotide repeat modifies expressivity of X-linked dystonia parkinsonism.

Annals of neurology
2020

Voice and swallowing dysfunction in X-linked dystonia parkinsonism.

The Laryngoscope
2018

Corrigendum: Validation of a Questionnaire for Distinguishing X-Linked Dystonia Parkinsonism From Its Mimics.

Frontiers in neurology
2019

Association of Pallidal Neurostimulation and Outcome Predictors With X-linked Dystonia Parkinsonism.

JAMA neurology
2018

Long-Term Outcomes of Bilateral Pallidal Deep Brain Stimulation for X-Linked Dystonia and Parkinsonism.

Stereotactic and functional neurosurgery
2018

Transient Generalized Chorea in Influenza A Encephalopathy.

Tremor and other hyperkinetic movements (New York, N.Y.)
2018

Validation of a Questionnaire for Distinguishing X-Linked Dystonia Parkinsonism From Its Mimics.

Frontiers in neurology
2019

Eye movement deficits in X-linked dystonia-parkinsonism are related to striatal degeneration.

Parkinsonism &amp; related disorders
2019

Long-term outcomes of pallidal deep brain stimulation in X-linked dystonia parkinsonism (XDP): Up to 84 months follow-up and review of literature.

Parkinsonism &amp; related disorders
2018

Basal ganglia and cerebellar pathology in X-linked dystonia-parkinsonism.

Brain : a journal of neurology
2018

An integrated OMICS approach unravels the elusive genetic cause of X-linked dystonia-parkinsonism.

Movement disorders : official journal of the Movement Disorder Society
2018

Genome editing in induced pluripotent stem cells rescues TAF1 levels in X-linked dystonia-parkinsonism.

Movement disorders : official journal of the Movement Disorder Society
2018

Altered glutamate response and calcium dynamics in iPSC-derived striatal neurons from XDP patients.

Experimental neurology
2018

Increased insula-putamen connectivity in X-linked dystonia-parkinsonism.

NeuroImage. Clinical
2018

Dissecting the Causal Mechanism of X-Linked Dystonia-Parkinsonism by Integrating Genome and Transcriptome Assembly.

Cell
2018

Solving Mendelian Mysteries: The Non-coding Genome May Hold the Key.

Cell
2018

Stem Cells Engineered During Different Stages of Reprogramming Reveal Varying Therapeutic Efficacies.

Stem cells (Dayton, Ohio)
2017

Disease onset in X-linked dystonia-parkinsonism correlates with expansion of a hexameric repeat within an SVA retrotransposon in TAF1.

Proceedings of the National Academy of Sciences of the United States of America
2017

Validation of the XDP-MDSP rating scale for the evaluation of patients with X-linked dystonia-parkinsonism.

NPJ Parkinson's disease
2017

Clinicopathological Phenotype and Genetics of X-Linked Dystonia-Parkinsonism (XDP; DYT3; Lubag).

Brain sciences
2018

The Basal Ganglia Striosomes Affect the Modulation of Conflicts by Subliminal Information-Evidence from X-Linked Dystonia Parkinsonism.

Cerebral cortex (New York, N.Y. : 1991)
2017

Dysfunctions in striatal microstructure can enhance perceptual decision making through deficits in predictive coding.

Brain structure &amp; function
2017

Striatal dysfunction in X-linked dystonia-parkinsonism is associated with disease progression.

European journal of neurology
2017

Sonographic alteration of substantia nigra is related to parkinsonism-predominant course of X-linked dystonia-parkinsonism.

Parkinsonism &amp; related disorders
2017

Striosomal dysfunction affects behavioral adaptation but not impulsivity-Evidence from X-linked dystonia-parkinsonism.

Movement disorders : official journal of the Movement Disorder Society
2017

X-linked Dystonia-Parkinsonism patient cells exhibit altered signaling via nuclear factor-kappa B.

Neurobiology of disease
2016

Neuroanatomical changes extend beyond striatal atrophy in X-linked dystonia parkinsonism.

Parkinsonism &amp; related disorders
2016

Evidence of TAF1 dysfunction in peripheral models of X-linked dystonia-parkinsonism.

Cellular and molecular life sciences : CMLS
2016

Decreased N-TAF1 expression in X-linked dystonia-parkinsonism patient-specific neural stem cells.

Disease models &amp; mechanisms
2016

Genome Editing in Human Pluripotent Stem Cells: Approaches, Pitfalls, and Solutions.

Cell stem cell
2015

Biochemical mechanisms of pallidal deep brain stimulation in X-linked dystonia parkinsonism.

Parkinsonism &amp; related disorders
2015

Neurophysiological fingerprints of X-linked dystonia-parkinsonism: A model basal ganglia disease.

Movement disorders : official journal of the Movement Disorder Society
2015

New insights into the genetics of X-linked dystonia-parkinsonism (XDP, DYT3).

European journal of human genetics : EJHG

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Distonia-Parkinsonismo ligado ao X.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Distonia-Parkinsonismo ligado ao X

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Alterations in energy production in a Drosophila model for the X-linked dystonia-parkinsonism-related Taf1 deficiency.
    Frontiers in aging neuroscience· 2026· PMID 41777671mais citado
  2. MSH3 is a genetic modifier of somatic repeat instability in X-linked dystonia parkinsonism.
    American journal of human genetics· 2026· PMID 41443196mais citado
  3. Therapeutic targeting of alternative splicing caused by a lethal noncoding structural variant in X-linked dystonia parkinsonism.
    medRxiv : the preprint server for health sciences· 2025· PMID 41282719mais citado
  4. A hexamer tandem repeat RNA embedded within an SVA retrotransposon drives R-loop formation and neurodegeneration.
    Cell reports· 2025· PMID 40540399mais citado
  5. Engineering of CD63 Enables Selective Extracellular Vesicle Cargo Loading and Enhanced Payload Delivery.
    Journal of extracellular vesicles· 2025· PMID 40527733mais citado
  6. Genome writing to dissect consequences of SVA retrotransposon disease X-Linked Dystonia Parkinsonism.
    bioRxiv· 2025· PMID 41279153recente
  7. Myelin pathology is a key feature of X-linked Dystonia Parkinsonism.
    bioRxiv· 2025· PMID 41278988recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:53351(Orphanet)
  2. OMIM OMIM:314250(OMIM)
  3. MONDO:0010747(MONDO)
  4. Distonia e Espasticidade(PCDT · Ministério da Saúde)
  5. GARD:10533(GARD (NIH))
  6. Variantes catalogadas(ClinVar)
  7. Busca completa no PubMed(PubMed)
  8. Q3042159(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Distonia-Parkinsonismo ligado ao X
Compêndio · Raras BR

Distonia-Parkinsonismo ligado ao X

ORPHA:53351 · MONDO:0010747
🇧🇷 Brasil SUS
Geral
Prevalência
<1 / 1 000 000
Herança
Not applicable, X-linked recessive
CID-10
G24.1 · Distonia familiar idiopática
CID-11
Início
Adult
Prevalência
0.0 (Europe)
MedGen
UMLS
C1839130
Repurposing
2 candidatos
procyclidineacetylcholine receptor antagonist
trihexyphenidyl
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades